3.84
-0.08 (-2.04%)
| Previous Close | 3.92 |
| Open | 3.96 |
| Volume | 454,915 |
| Avg. Volume (3M) | 395,525 |
| Market Cap | 202,721,280 |
| Price / Sales | 4.56 |
| Price / Book | 28.45 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Profit Margin | -216.24% |
| Operating Margin (TTM) | -151.10% |
| Diluted EPS (TTM) | -1.92 |
| Quarterly Revenue Growth (YOY) | 92.60% |
| Total Debt/Equity (MRQ) | 395.59% |
| Current Ratio (MRQ) | 5.48 |
| Operating Cash Flow (TTM) | -69.98 M |
| Levered Free Cash Flow (TTM) | -46.02 M |
| Return on Assets (TTM) | -49.20% |
| Return on Equity (TTM) | -934.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | scPharmaceuticals Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 3.5 |
| Average | 0.75 |
|
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.08% |
| % Held by Institutions | 76.64% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 May 2025 | Announcement | scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update |
| 07 May 2025 | Announcement | scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 |
| 01 May 2025 | Announcement | scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |